Middle East And Africa Transfection Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
199.72
307.44
2020
2028
 Período de previsão |
2021 –2028 |
 Tamanho do mercado (ano base ) | USD 199.72 |
 Tamanho do mercado ( Ano de previsão) | USD 307.44 |
 CAGR |
% |
| Principais participantes do mercado |
Mercado de transfecção do Médio Oriente e África, por tipo (transfecção transitória, transfecção estável), métodos (métodos não virais, métodos virais), métodos de transfecção CRISPR (métodos não virais, métodos virais), produtos (reagentes e kits, instrumento, software ), Organismo (células de mamíferos, plantas, fungos, vírus, bactérias), Tipos de moléculas (DNA plasmídeo, pequeno RNA interferente (siRNA), proteínas, oligonucleótidos de DNA, complexos de ribonucleoproteínas (RNPs), outros), Aplicação ( aplicação in vitro, Aplicação in vivo, bioprodução, outros), estágio (investigação, pré-clínica, fases clínicas, comercial), utilizador final (biofarmacêutica, organizações de investigação por contrato (CROs), organização de fabrico por contrato/organização de desenvolvimento e fabrico contratada (CMOs/CDMOs), academia, Hospitais, laboratórios clínicos, outros), canal de distribuição (licitação direta, vendas a retalho, outros), país (Arábia Saudita, África do Sul, Emirados Árabes Unidos, Israel, Egito, resto do Médio Oriente e África), tendências e previsões do setor até 2028
Análise de Mercado e Insights: Mercado de Transfecção no Médio Oriente e África
Espera-se que o mercado de transfecção do Médio Oriente e África ganhe crescimento de mercado no período previsto de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 8,0% no período previsto de 2021 a 2028 e prevê-se que atinja os 33,81 milhões de dólares até 2028. A crescente procura de genes quiméricos e o aumento da ocorrência de doenças crónicas são os principais impulsionadores da procura do mercado no período previsto.
A transfecção envolve a introdução de ácido nucleico nas células eucarióticas por métodos virais e não virais. O método de transfecção pode superar o desafio associado à transferência da membrana carregada negativamente. Um produto químico como o fosfato de cálcio e o dietilaminoetil (DEAE) -dextrano ou reagentes catiónicos à base de lípidos reagem com o revestimento externo do ADN. Neutraliza a carga negativa global, além de transmitir a quantidade positiva à molécula e, portanto, permite a entrega do ADN. Métodos físicos como a eletroporação criam poros minúsculos na membrana celular através da aplicação de voltagem elétrica, permitindo a entrada de ADN diretamente no citoplasma. O DEAE-dextrano é utilizado para transfecção transitória; no entanto, a lipofecção pode atingir uma transfecção estável e, por isso, pode ser utilizada para a expressão proteica a longo prazo. A transfecção mediada por fosfato de cálcio também pode ser utilizada para a transfecção estável. O método viral de transfecção atinge uma elevada eficiência de transfecção e é utilizado em várias fases do desenvolvimento de produtos biofarmacêuticos.
O aumento da prevalência de doenças crónicas está a funcionar como um impulsionador do crescimento do mercado de transfecção. O elevado custo dos instrumentos funciona como uma restrição ao crescimento do mercado de transfecção. A exploração de mercados emergentes está a funcionar como uma oportunidade para o crescimento do mercado de transfecção. O procedimento de aprovação longo atua como um desafio para o crescimento do mercado de transfeção.
O relatório de mercado de transfecção fornece detalhes sobre a quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações de mercado , aprovações de produtos , decisões estratégicas, lançamentos de produtos, geografia expansões e inovações tecnológicas no mercado. Para compreender a análise e o cenário de mercado, contacte-nos para um briefing analítico.
Âmbito e dimensão do mercado de transfecção no Médio Oriente e África
O mercado de transfecção é segmentado com base no tipo, métodos, métodos de transfecção CRISPR, produtos, organismo, tipos de molécula, aplicação, estágio, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base no tipo, o mercado de transfecção está segmentado em transfecção transitória e transfecção estável. Em 2021, o segmento de transfecção transitória está a dominar, uma vez que este método obtém resultados de transfecção em 3 a 7 dias com elevadas taxas de eficiência de transfecção.
- Com base nos métodos, o mercado da transfecção está segmentado em métodos não virais e métodos virais . Em 2021, o segmento dos métodos não virais está a dominar todos os tipos de transfeção, incluindo a transfeção CRISPR (repetições palindrómicas curtas agrupadas regularmente interespaçadas), uma vez que estes métodos proporcionam uma elevada eficiência de transfeção e superam as hipóteses de infeções induzidas por métodos de transfeção viral .
- Com base nos métodos de transfecção CRISPR, o mercado de transfecção está segmentado em métodos não virais e métodos virais. Em 2021, o segmento dos métodos não virais está a dominar a transfeção CRISPR (repetições palindrómicas curtas agrupadas regularmente interespaçadas), uma vez que permite a entrega eficiente de sequências CRISPR às linhas celulares alvo.
- Com base nos produtos, o mercado da transfecção está segmentado em reagentes e kits, instrumentos e software. Em 2021, o segmento de reagentes e kits está a dominar, uma vez que são utilizados para aumentar a eficácia do processo de transfeção em várias experiências genéticas.
- Com base no organismo, o mercado da transfecção está segmentado em células de mamíferos, plantas, fungos, vírus e bactérias . Em 2021, o segmento das células dos mamíferos está a dominar, uma vez que são amplamente utilizadas para a produção de anticorpos monoclonais, proteínas, uroquinase, hormona folículo estimulante e outros produtos, em comparação com outros tipos de linhagens celulares.
- Com base nos tipos de moléculas, o mercado de transfecção está segmentado em ADN plasmídico, pequeno ARN interferente (siRNA), proteínas, oligonucleótidos de ADN, complexos de ribonucleoproteínas (RNPs) e outros. Em 2021, o segmento de ADN plasmídico está a dominar, uma vez que um grande número de tecnologias de transfecção foram inicialmente desenvolvidas para a transferência de ADN plasmídico para células.
- Com base na aplicação, o mercado da transfecção está segmentado em aplicação in vitro , aplicação in vivo, bioprodução e outros. Em 2021, o segmento de aplicação in vitro está a dominar, uma vez que proporciona a entrega de moléculas de ácido nucleico de carga em células cultivadas, o que tem um papel crucial na investigação, bem como na produção comercial de moléculas.
- Com base no estágio, o mercado da transfecção está segmentado em fases de investigação, pré-clínica , clínica e comercial. Em 2021, o segmento de investigação está a dominar devido à crescente procura de expressão genética na indústria da biologia sintética e outras aplicações.
- Com base no utilizador final, o mercado de transfecção está segmentado em biofarmacêutica , organizações de investigação por contrato (CROs), organizações de fabrico por contrato/organizações de desenvolvimento e fabrico por contrato (CMOs/CDMOs), academia, hospitais, laboratórios clínicos e outros. Em 2021, o segmento biofarmacêutico detém a maior quota de mercado devido à crescente procura de melhoria da eficiência e rapidez na produção das linhas celulares desejadas.
- Com base no canal de distribuição, o mercado de transfecção está segmentado em licitação direta, vendas a retalho e outros. Em 2021, o segmento de licitação direta está a dominar, uma vez que é a principal fonte de aquisição entre os diferentes utilizadores finais.
Análise do mercado de transfecção no Médio Oriente e África a nível de país
O mercado de transfecção é analisado e são fornecidas informações sobre o tamanho do mercado com base no país, tipo, métodos, métodos de transfecção CRISPR, produtos, organismo, tipos de molécula, aplicação, estágio, utilizador final e canal de distribuição, conforme referenciado acima.
Os países abrangidos pelo relatório de mercado de transfecção do Médio Oriente e África são a Arábia Saudita, África do Sul, Emirados Árabes Unidos, Israel, Egito, Resto do Médio Oriente e África.
Prevê-se que o Médio Oriente e África cresçam com uma taxa de crescimento substancial no período previsto de 2021 a 2028, uma vez que os países do Médio Oriente e África estão focados na utilização de biofármacos na produção de proteínas e também na utilização das melhores opções terapêuticas para o tratamento de doenças crónicas crescentes. A África do Sul está a dominar o Médio Oriente e África devido ao crescente foco na geração de linhas celulares estáveis e na produção de vírus.
A secção de países do relatório sobre o mercado de transfecção também fornece fatores individuais que impactam o mercado e alterações na regulamentação do mercado nacional que impactam as tendências atuais e futuras do mercado. Pontos de dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e a disponibilidade de marcas do Médio Oriente e de África e os desafios enfrentados devido à grande ou escassa concorrência das marcas locais e nacionais, bem como o impacto dos canais de venda, são considerados quando se fornece uma análise de previsão dos dados do país.
Os níveis crescentes de investimento e a procura crescente de genes quiméricos estão a impulsionar o crescimento do mercado de transfecção
O mercado de transfecção também fornece uma análise de mercado detalhada para o crescimento de cada país na indústria de transfecção com vendas de medicamentos para transfecção, impacto do avanço na tecnologia de transfecção e mudanças nos cenários regulamentares com o seu apoio ao mercado de transfecção. Os dados estão disponíveis para o período histórico de 2010 a 2018.
Análise do cenário competitivo e da quota de mercado da transfecção
O panorama competitivo do mercado de transfecção no Médio Oriente e em África fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produto, aprovações de produto, patentes, largura e amplitude do produto, domínio da aplicação, curva de vida da tecnologia. Os pontos de dados fornecidos acima estão apenas relacionados com o foco da empresa no mercado de transfecção do Médio Oriente e África.
As principais empresas que operam no mercado de transfecção do Médio Oriente e África são a Mirus Bio LLC., Promega Corporation, Bio-Rad Laboratories, Inc., Merck KGaA, Lonza, MaxCyte, Inc., Cytiva, Thermofisher Scientific Inc., QIAGEN, OriGene Technologies, Inc. e SignaGen Laboratories, entre outros. Os analistas do DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
Muitos lançamentos e acordos de produtos são também iniciados por empresas de todo o mundo, o que também está a acelerar o mercado de transfecção.
Por exemplo,
- Em novembro de 2020, a Thermofisher Scientific Inc. colaborou com a Northeastern University para fortalecer a inovação e as capacidades da indústria biofarmacêutica e das terapias genéticas e celulares. A empresa está continuamente envolvida no fabrico de reagentes e técnicas inovadoras e avançadas para fornecer sensibilidade e precisão às experiências em curso e ao desenvolvimento de medicamentos. Esta colaboração permitiu à empresa impulsionar o crescimento de reagentes e ferramentas valiosos e altamente eficientes utilizados no procedimento de transfecção.
- Em julho de 2019, a Mirus Bio LLC. Lançamos um novo produto de qualidade testada, o reagente de transfecção TransIT-VirusGEN SELECT, indicado para uma administração eficiente de ADN, de modo a produzir vectores virais de grande escala e alto título. Este reagente tem a capacidade de melhorar a entrega de ADN de vetor de embalagem e transferência para tipos de células HEK 293 aderentes e suspensões de ADN. O lançamento deste produto melhorou o portfólio de produtos da empresa e impulsionou a sua receita.
A colaboração, o lançamento de produtos, a expansão de negócios, prémios e reconhecimentos, joint ventures e outras estratégias dos participantes do mercado estão a aumentar o mercado da empresa no mercado de transfecção, o que também traz o benefício para a organização melhorar a sua oferta de transfecção.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA TRANSFECTION MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TRANSIENT TRANSFECTION OF TRANSFECTION LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 TOTAL ADDRESSABLE MARKET
4.1.1 BY METHOD/MODALITY
4.1.2 BY END USER
4.1.3 BY APPLICATION
4.1.4 BY STAGE
4.2 EARLY AND LATE STAGE CELL LINE DEVELOPMENT FOR BIOPHARMA AND VIRAL VECTOR PRODUCTION FOR GENE THERAPY
4.2.1 THE LIST OF APPROVED ANTIBODIES PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS AND LIST OF SELECTABLE MARKERS USED IN MAMMALIAN EXPRESSION VECTORS
5 REGULATORY FRAMEWORK
5.1 EUROPEAN UNION REGULATORY SCENARIO
5.2 U.S. REGULATORY SCENARIO
5.3 JAPAN REGULATORY SCENARIO
5.4 CHINA REGULATORY SCENARIO
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES
6.1.2 DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS
6.1.3 GROWING DEMAND OF CHIMERIC GENES
6.1.4 LARGE-SCALE TRANSFECTIONS USED IN CLINICAL RESEARCH
6.1.5 UTILIZATION OF BIOPHARMACEUTICALS IN THE PRODUCTION OF PROTEINS
6.2 RESTRAINTS
6.2.1 HIGH COST OF TRANSFECTION PRODUCTS
6.2.2 SELECTIVE EFFECTIVENESS OF TRANSFECTION REAGENTS
6.2.3 CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE
6.3 OPPORTUNITIES
6.3.1 EXPLORATION OF EMERGING MARKET
6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.3 INCREASING GOVERNMENT SUPPORT
6.3.4 SURGING LEVEL OF INVESTMENT
6.4 CHALLENGES
6.4.1 LONG APPROVAL PROCEDURE
6.4.2 LACK OF SAFETY LEVEL LAB FOR VIRUS ASSOCIATED TRANSFECTION
6.4.3 LACK OF TRAINED PROFESSIONALS
7 COVID-19 IMPACT OF MIDDLE EAST AND AFRICA TRANSFECTION MARKET IN HEALTHCARE INDUSTRY
7.1 OVERVIEW
7.2 IMPACT ON THE PRICE
7.3 IMPACT ON DEMAND
7.4 IMPACT ON SUPPLY CHAIN
7.5 STRATEGIC INITIATIVE BY MANUFACTURERS
7.6 CONCLUSION
8 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY TYPE
8.1 OVERVIEW
8.2 TRANSIENT TRANSFECTION
8.2.1 BY STAGE
8.2.1.1 RESEARCH
8.2.1.2 PRECLINICAL
8.2.1.3 CLINICAL PHASES
8.2.1.4 COMMERCIAL
8.2.2 BY PRODUCT
8.2.2.1 REAGENT & KITS
8.2.2.2 INSTRUMENTS
8.2.2.3 SOFTWARE
8.3 STABLE TRANSECTION
8.3.1 BY STAGE
8.3.1.1 RESEARCH
8.3.1.2 PRECLINICAL
8.3.1.3 CLINICAL PHASES
8.3.1.4 COMMERCIAL
8.3.2 BY PRODUCT
8.3.2.1 REAGENT & KITS
8.3.2.2 INSTRUMENTS
8.3.2.3 SOFTWARE
9 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY METHODS
9.1 2.1 OVERVIEW
9.2 NON- VIRAL METHODS
9.2.1 CHEMICAL
9.2.1.1 Lipofection Method
9.2.1.2 Calcium Phosphate Precipitation Method
9.2.1.3 Polyethylenimine (PEI)–DNA Condensation Method
9.2.1.4 Others
9.2.2 PHYSICAL
9.2.2.1 Electroporation
9.2.2.2 Direct Microinjection
9.2.2.3 Biolistic Particle Delivery/ Particle Bombardment
9.2.2.4 Magnetofection
9.2.2.5 Sonoporation
9.2.2.6 Others
9.3 VIRAL METHODS
9.3.1 RETROVIRUS TRANSFECTION
9.3.2 ADENOVIRUS TRANSFECTION
9.3.3 LENTIVIRUS TRANSFECTION
9.3.4 OTHERS
10 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY METHODS
10.1 OVERVIEW
10.2 NON- VIRAL METHODS
10.2.1 CHEMICAL
10.2.1.1 Lipofection Method
10.2.1.2 Calcium Phosphate Precipitation Method
10.2.1.3 Polyethylenimine (PEI)–DNA Condensation Method
10.2.1.4 Others
10.2.2 PHYSICAL
10.2.2.1 Electroporation
10.2.2.2 Direct Microinjection
10.2.2.3 Biolistic Particle Delivery/ Particle Bombardment
10.2.2.4 Magnetofection
10.2.2.5 Sonoporation
10.2.2.6 Others
10.3 VIRAL METHODS
10.3.1 RETROVIRUS TRANSFECTION
10.3.2 ADENOVIRUS TRANSFECTION
10.3.3 LENTIVIRUS TRANSFECTION
10.3.4 OTHERS
11 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY PRODUCTS
11.1 OVERVIEW
11.2 REAGENTS & KITS
11.2.1 CATIONIC LIPIDS
11.2.1.1 Liposomal Reagents
11.2.1.1.1 L-Dioleoyl Phosphatidylethanolamine (DOPE)
11.2.1.1.2 DOTAP [1,2-Dioleoyloxy-3-Trimethylammonium Propane]
11.2.1.1.3 DOTMA [N-[1(2,3-Dioleoyloxy)Propyl]-N,N,N-Trimethylammonium Chloride]
11.2.1.1.4 Others
11.2.1.2 Non-Liposomal Reagents
11.2.1.2.1 DNA Transfection Reagent
11.2.1.2.2 siRNA Transfection Reagent
11.2.1.2.3 Others
11.2.2 CATIONIC POLYMER
11.2.2.1 DEAE-Dextran
11.2.2.2 Polybrene
11.2.2.3 Polyethyleneimine
11.2.2.4 Dendrimers
11.2.2.5 Others
11.2.3 NANOPARTICLES
11.2.3.1 Systemic Intravenous Injection
11.2.3.2 Direct Intratumoral Injection
11.2.4 KITS
11.2.4.1 Transporter Transfection Reagent
11.2.4.2 GMP Transfection Reagent
11.2.4.3 Neon Electroporation
11.2.4.4 Cellfectin Ii Transfection Reagent
11.2.4.5 DMRIE-C Transfection Reagent
11.2.4.6 Lipofectamine Transfection Reagent
11.2.4.7 Lipofectin Transfection Reagent
11.2.4.8 Oligofectamine Transfection Reagent
11.2.4.9 Optifect Transfection Reagent
11.2.4.10 Cell Specific Transfection Reagent
11.2.4.11 Gene Gun Kit
11.2.4.12 Plasmid Transfection Reagent
11.2.4.13 Others
11.2.5 CUVETTE CHAMBER
11.2.6 OTHERS
11.3 INSTRUMENT
11.3.1 ELECTROPORATION SYSTEM
11.3.1.1 Neon Transfection System
11.3.1.2 Others
11.3.2 ELECTRO-CELL FUSION GENERATOR
11.3.3 ELECTRO-KINETIC TRANSFECTION SYSTEM
11.3.4 HEPTA SYSTEM
11.3.5 TUBING PREP STATION
11.3.6 RT-PCR
11.3.7 GUN SYSTEM
11.3.8 MICROPLATE READER
11.3.9 SONOPORATION SYSTEM
11.3.10 MICROSCOPES
11.3.11 OTHERS
12 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY ORGANISM
12.1 OVERVIEW
12.2 MAMMALIAN CELLS
12.3 PLANTS
12.4 FUNGI
12.5 VIRUS
12.6 BACTERIA
13 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY TYPES OF MOLECULE
13.1 OVERVIEW
13.2 PLASMID DNA
13.3 SMALL INTERFERING RNA (SIRNA)
13.4 PROTEINS
13.5 DNA OLIGONUCLEOTIDES
13.6 RIBONUCLEOPROTEIN COMPLEXES (RNPS)
13.7 OTHERS
14 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY APPLICATION
14.1 OVERVIEW
14.2 BY TYPE
14.2.1 IN VITRO APPLICATION
14.2.1.1 Gene Expression
14.2.1.2 RNA Interference
14.2.2 IN VIVO APPLICATION
14.2.2.1 Gene Therapy
14.2.2.2 Cellular-Based Therapy
14.2.3 BIOPRODUCTION
14.2.3.1 Antibody/Protein Production
14.2.3.2 Virus Production
14.2.4 OTHERS
14.3 BY INDUSTRY
14.3.1 SYNTHETIC BIOLOGY
14.3.1.1 Biopharma
14.3.1.2 Monoclonal Antibodies (mAbs)
14.3.1.3 Recombinant Proteins
14.3.1.4 Biofuels
14.3.1.5 Cell Line Development
14.3.1.6 Flavors & Fragrances
14.3.1.7 Enzyme Engineering & Production
14.3.1.8 Specialty Chemicals
14.3.2 AGRICULTURE
14.3.3 OTHERS
15 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY STAGES
15.1 OVERVIEW
15.2 RESEARCH
15.3 PRECLINICAL
15.4 CLINICAL PHASES
15.5 COMMERCIAL
16 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY END USER
16.1 OVERVIEW
16.2 BIOPHARMA
16.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
16.4 CONTRACT MANUFACTURING ORGANIZATION/ CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CMOS/CDMOS)
16.5 ACADEMIA
16.6 HOSPITALS
16.7 CLINICAL LABS
16.8 OTHERS
17 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDERS
17.3 RETAIL SALES
17.4 OTHERS
18 MIDDLE EAST AND AFRICA TRASNFECTION MARKET, BY GEOGRAPHY
18.1 MIDDLE EAST & AFRICA
18.1.1 SOUTH AFRICA
18.1.2 SAUDI ARABIA
18.1.3 UAE
18.1.4 ISRAEL
18.1.5 EGYPT
18.1.6 REST OF MIDDLE EAST & AFRICA
19 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
20 SWOT ANALYSIS
21 COMPANY PROFILE
21.1 THERMOFISHER SCIENTIFIC INC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 ROCHE MOLECULAR SYSTEMS, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMAPYN SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 QIAGEN
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.4 PROMEGA CORPORATION
21.4.1 COMPANY SNAPSHOT
21.4.2 COMPANY SHARE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENTS
21.5 TAKARA BIO INC.
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 BIO-RAD LABORATORIES, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANANLYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 LONZA
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANANLYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 CYTIVA
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENTS
21.9 ALTOGEN BIOSYSTEMS
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENTS
21.1 AMYRIS
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENTS
21.11 APPLIED BIOLOGICAL MATERIALS INC. (ABM)
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENT
21.12 AUTOLUS
21.12.1 COMPANY SNAPSHOT
21.12.2 PRODUCT PORTFOLIO
21.12.3 RECENT DEVELOPMENTS
21.13 AVANTI POLAR LIPIDS (A SUBSIDIARY OF CRODA INTERNATIONAL PLC)
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENTS
21.15 CODEXIS
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 CONAGEN, INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 PRODUCT PORTFOLIO
21.16.3 RECENT DEVELOPMENTS
21.17 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)
21.17.1 COMPANY SNAPSHOT
21.17.2 REVENUE ANANLYSIS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENT
21.18 GENLANTIS INC.
21.18.1 COMPANY SNAPSHOT
21.18.2 PRODUCT PORTFOLIO
21.18.3 RECENT DEVELOPMENTS
21.19 GENO TECHNOLOGY INC., USA
21.19.1 COMPANY SNAPSHOT
21.19.2 PRODUCT PORTFOLIO
21.19.3 RECENT DEVELOPMENTS
21.2 GINKGO BIOWORKS
21.20.1 COMPANY SNAPSHOT
21.20.2 PRODUCT PORTFOLIO
21.20.3 RECENT DEVELOPMENTS
21.21 IMPOSSIBLE FOODS INC.
21.21.1 COMPANY SNAPSHOT
21.21.2 PRODUCT PORTFOLIO
21.21.3 RECENT DEVELOPMENTS
21.22 MAXCYTE, INC.
21.22.1 COMPANY SNAPSHOT
21.22.2 REVENUE ANALYSIS
21.22.3 PRODUCT PORTFOLIO
21.22.4 RECENT DEVELOPMENTS
21.23 MERCK KGAA
21.23.1 COMPANY SNAPSHOT
21.23.2 REVENUE ANALYSIS
21.23.3 PRODUCT PORTFOLIO
21.23.4 RECENT DEVELOPMENTS
21.24 MIRUS BIO LLC.
21.24.1 COMPANY SNAPSHOT
21.24.2 PRODUCT PORTFOLIO
21.24.3 RECENT DEVELOPMENTS
21.25 ORIGENE TECHNOLOGIES, INC.
21.25.1 COMPANY SNAPSHOT
21.25.2 PRODUCT PORTFOLIO
21.25.3 RECENT DEVELOPMENTS
21.26 PERKINELMER CHEMAGEN TECHNOLOGIE GMBH (A SUBSIDIARY OF PERKINELMER INC.)
21.26.1 COMPANY SNAPSHOT
21.26.2 REVENUE ANANLYSIS
21.26.3 PRODUCT PORTFOLIO
21.26.4 RECENT DEVELOPMENTS
21.27 POLYPLUS TRANSFECTION
21.27.1 COMPANY SNAPSHOT
21.27.2 PRODUCT PORTFOLIO
21.27.3 RECENT DEVELOPMENTS
21.28 POSEIDA THERAPEUTICS, INC.
21.28.1 COMPANY SNAPSHOT
21.28.2 PRODUCT PORTFOLIO
21.28.3 RECENT DEVELOPMENTS
21.29 R&D SYSTEMS, INC.
21.29.1 COMPANY SNAPSHOT
21.29.2 PRODUCT PORTFOLIO
21.29.3 RECENT DEVELOPMENT
21.3 SBS GENETECH
21.30.1 COMPANY SNAPSHOT
21.30.2 PRODUCT PORTFOLIO
21.30.3 RECENT DEVELOPMENTS
21.31 SIGNAGEN LABORATORIES
21.31.1 COMPANY SNAPSHOT
21.31.2 PRODUCT PORTFOLIO
21.31.3 RECENT DEVELOPMENTS
21.32 TWIST BIOSCIENCE
21.32.1 COMPANY SNAPSHOT
21.32.2 REVENUE ANALYSIS
21.32.3 PRODUCT PORTFOLIO
21.32.4 RECENT DEVELOPMENTS
21.33 VERVE THERAPEUTICS, INC.
21.33.1 COMPANY SNAPSHOT
21.33.2 PRODUCT PORTFOLIO
21.33.3 RECENT DEVELOPMENTS
21.34 ZYMERGEN INC.
21.34.1 COMPANY SNAPSHOT
21.34.2 PRODUCT PORTFOLIO
21.34.3 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
Lista de Tabela
LIST OF TABLES
TABLE 1 LIST OF APPROVED ANTIBODIES PRODUCED IN CHO CELLS
TABLE 2 EU DIRECTIVES AND REGULATIONS RELATED TO CLINICAL TRIALS INVOLVING GTMPS
TABLE 3 GOVERNMENT ENTITIES THAT ARE IN CHARGE OF TYPE 2 USES
TABLE 4 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA TRANSIENT TRANSFECTION IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA NON- VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA NON- VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA SOFTWARE BY INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA MAMMALIAN CELLS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA PLANTS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA FUNGI IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA VIRUS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA BACTERIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA PLASMID DNA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA BACTERIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA PROTEINS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA DNA OLIGONUCLEOTIDES IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA RIBONUCLEOPROTEIN COMPLEXES (RNPS) IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA BACTERIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICATRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA IN VITRO APPLICATION IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA IN VIVO APPLICATION IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA BIOPRODUCTION IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA AGRICULTURE IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 63 MIDDLE EAST AND AFRICA RESEARCH IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 64 MIDDLE EAST AND AFRICA PRE-CLINICAL IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)
TABLE 65 MIDDLE EAST AND AFRICA CLINICAL PHASES IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 66 MIDDLE EAST AND AFRICA COMMERCIAL IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 67 NORTH AMERICA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 68 MIDDLE EAST AND AFRICA BIOPHARMA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 69 MIDDLE EAST AND AFRICA CONTRACT RESEARCH ORGANIZATIONS (CROS) IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 70 MIDDLE EAST AND AFRICA CONTRACT MANUFACTURING ORGANIZATION/ CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CMOS/CDMOS) IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 71 MIDDLE EAST AND AFRICA ACADEMIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 72 MIDDLE EAST AND AFRICA HOSPITALS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 73 MIDDLE EAST AND AFRICA CLINICAL LABS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 74 MIDDLE EAST AND AFRICA OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 75 NORTH AMERICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 76 MIDDLE EAST AND AFRICA DIRECT TENDER IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 77 MIDDLE EAST AND AFRICA RETAIL SALES IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 78 MIDDLE EAST AND AFRICA OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 79 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY REGION, 2018-2028 (USD MILLION)
TABLE 80 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 81 MIDDLE EAST & AFRICA TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 82 MIDDLE EAST & AFRICA TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 MIDDLE EAST & AFRICA STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 MIDDLE EAST & AFRICA STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 85 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 86 MIDDLE EAST & AFRICA NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 87 MIDDLE EAST & AFRICA CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 88 MIDDLE EAST & AFRICA PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 89 MIDDLE EAST & AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 90 MIDDLE EAST & AFRICA CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 91 MIDDLE EAST & AFRICA NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 92 MIDDLE EAST & AFRICA CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 93 MIDDLE EAST & AFRICA PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 94 MIDDLE EAST & AFRICA VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 95 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 96 MIDDLE EAST & AFRICA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 97 MIDDLE EAST & AFRICA CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 98 MIDDLE EAST & AFRICA LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 99 MIDDLE EAST & AFRICA NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 100 MIDDLE EAST & AFRICA CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 101 MIDDLE EAST & AFRICA KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 102 MIDDLE EAST & AFRICA NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 103 MIDDLE EAST & AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 104 MIDDLE EAST & AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 105 MIDDLE EAST & AFRICA ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 106 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 107 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 108 MIDDLE EAST & AFRICATRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 109 MIDDLE EAST & AFRICA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 110 MIDDLE EAST & AFRICA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 111 MIDDLE EAST & AFRICA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 112 MIDDLE EAST & AFRICA TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 113 MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 114 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 115 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 116 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 117 SOUTH AFRICA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 118 SOUTH AFRICA TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 119 SOUTH AFRICA TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 120 SOUTH AFRICA STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 121 SOUTH AFRICA STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 SOUTH AFRICA TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 123 SOUTH AFRICA NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 124 SOUTH AFRICA CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 125 SOUTH AFRICA PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 126 SOUTH AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 127 SOUTH AFRICA CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 128 SOUTH AFRICA NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 129 SOUTH AFRICA CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 130 SOUTH AFRICA PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 131 SOUTH AFRICA VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 132 SOUTH AFRICA TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 133 SOUTH AFRICA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 134 SOUTH AFRICA CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 135 SOUTH AFRICA LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 136 SOUTH AFRICA NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 137 SOUTH AFRICA CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 138 SOUTH AFRICA KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 139 SOUTH AFRICA NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 140 SOUTH AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 141 SOUTH AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 142 SOUTH AFRICA ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 143 SOUTH AFRICA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 144 SOUTH AFRICA TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 145 SOUTH AFRICA TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 146 SOUTH AFRICA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 147 SOUTH AFRICA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 148 SOUTH AFRICA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 149 SOUTH AFRICA TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 150 SOUTH AFRICA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 151 SOUTH AFRICA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 152 SOUTH AFRICA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 153 SOUTH AFRICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 154 SAUDI ARABIA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 155 SAUDI ARABIA TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 SAUDI ARABIA TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 SAUDI ARABIA STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 SAUDI ARABIA STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 159 SAUDI ARABIA TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 160 SAUDI ARABIA NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 161 SAUDI ARABIA CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 162 SAUDI ARABIA PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 163 SAUDI ARABIA VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 164 SAUDI ARABIA CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 165 SAUDI ARABIA NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 166 SAUDI ARABIA CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 167 SAUDI ARABIA PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 168 SAUDI ARABIA VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 169 SAUDI ARABIA TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 170 SAUDI ARABIA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 171 SAUDI ARABIA CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 172 SAUDI ARABIA LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 173 SAUDI ARABIA NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 174 SAUDI ARABIA CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 175 SAUDI ARABIA KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 176 SAUDI ARABIA NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 177 SAUDI ARABIA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 178 SAUDI ARABIA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 179 SAUDI ARABIA ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 180 SAUDI ARABIA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 181 SAUDI ARABIA TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 182 SAUDI ARABIA TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 183 SAUDI ARABIA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 184 SAUDI ARABIA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 185 SAUDI ARABIA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 186 SAUDI ARABIA TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 187 SAUDI ARABIA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 188 SAUDI ARABIA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 189 SAUDI ARABIA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 190 SAUDI ARABIA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 191 UAE TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 192 UAE TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 193 UAE TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 194 UAE STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 195 UAE STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 UAE TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 197 UAE NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 198 UAE CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 199 UAE PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 200 UAE VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 201 UAE CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 202 UAE NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 203 UAE CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 204 UAE PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 205 UAE VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 206 UAE TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 207 UAE REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 208 UAE CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 209 UAE LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 210 UAE NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 211 UAE CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 212 UAE KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 213 UAE NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 214 UAE INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 215 UAE INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 216 UAE ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 217 UAE TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 218 UAE TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 219 UAE TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 220 UAE IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 221 UAE IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 222 UAE BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 223 UAE TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 224 UAE SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 225 UAE TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 226 UAE TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 227 UAE TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 228 ISRAEL TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 229 ISRAEL TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 230 ISRAEL TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 231 ISRAEL STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 232 ISRAEL STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 233 ISRAEL TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 234 ISRAEL NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 235 ISRAEL CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 236 ISRAEL PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 237 ISRAEL VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 238 ISRAEL CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 239 ISRAEL NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 240 ISRAEL CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 241 ISRAEL PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 242 ISRAEL VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 243 ISRAEL TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 244 ISRAEL REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 245 ISRAEL CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 246 ISRAEL LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 247 ISRAEL NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 248 ISRAEL CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 249 ISRAEL KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 250 ISRAEL NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 251 ISRAEL INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 252 ISRAEL INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 253 ISRAEL ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 254 ISRAEL TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 255 ISRAEL TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 256 ISRAEL TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 257 ISRAEL IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 258 ISRAEL IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 259 ISRAEL BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 260 ISRAEL TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 261 ISRAEL SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 262 ISRAEL TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 263 ISRAEL TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 264 ISRAEL TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 265 EGYPT TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 266 EGYPT TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 267 EGYPT TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 268 EGYPT STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 269 EGYPT STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 EGYPT TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 271 EGYPT NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 272 EGYPT CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 273 EGYPT PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 274 EGYPT VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 275 EGYPT CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 276 EGYPT NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 277 EGYPT CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 278 EGYPT PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 279 EGYPT VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)
TABLE 280 EGYPT TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 281 EGYPT REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 282 EGYPT CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 283 EGYPT LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 284 EGYPT NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 285 EGYPT CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 286 EGYPT KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 287 EGYPT NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 288 EGYPT INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 289 EGYPT INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)
TABLE 290 EGYPT ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)
TABLE 291 EGYPT TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)
TABLE 292 EGYPT TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)
TABLE 293 EGYPT TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 294 EGYPT IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 295 EGYPT IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 296 EGYPT BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 297 EGYPT TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 298 EGYPT SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 299 EGYPT TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)
TABLE 300 EGYPT TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 301 EGYPT TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 302 REST OF MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)
Lista de Figura
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA TRANSFECTION MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 10 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: SEGMENTATION
FIGURE 12 INCREASING OCCURENCE OF CHRONIC DISEASES AND DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS IS DRIVING THE MIDDLE EAST AND AFRICA TRANSFECTION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 TRANSIENT TRANSFECTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA TRANSFECTION MARKET IN 2021 & 2028
FIGURE 14 APPROVAL PROCESS FOR GENE THERAPY IN CHINA
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA TRANSFECTION MARKET
FIGURE 16 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPE, 2020
FIGURE 17 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 18 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 19 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, 2020
FIGURE 21 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, 2020-2028 (USD MILLION)
FIGURE 22 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, CAGR (2021-2028)
FIGURE 23 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, 2020
FIGURE 25 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, 2020-2028 (USD MILLION)
FIGURE 26 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, CAGR (2021-2028)
FIGURE 27 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY PRODUCT, 2020
FIGURE 29 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY PRODUCT, 2020-2028 (USD MILLION)
FIGURE 30 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 31 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY ORGANISM, 2020
FIGURE 33 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY ORGANISM, 2020-2028 (USD MILLION)
FIGURE 34 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY ORGANISM, CAGR (2021-2028)
FIGURE 35 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY ORGANISM, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPES OF MOLECULE, 2020
FIGURE 37 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPES OF MOLECULE, 2020-2028 (USD MILLION)
FIGURE 38 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPES OF MOLECULE, CAGR (2021-2028)
FIGURE 39 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPES OF MOLECULE LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY APPLICATION, 2020
FIGURE 41 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY APPLICATION, 2020-2028 (USD MILLION)
FIGURE 42 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 43 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 44 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY STAGES, 2020
FIGURE 45 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY STAGES, 2020-2028 (USD MILLION)
FIGURE 46 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY STAGES, CAGR (2021-2028)
FIGURE 47 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY STAGES, LIFELINE CURVE
FIGURE 48 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY END USER, 2020
FIGURE 49 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 50 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY END USER, CAGR (2021-2028)
FIGURE 51 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 52 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 53 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 54 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 55 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 56 MIDDLE EAST & AFRICA TRANSFECTION MARKET: SNAPSHOT (2020)
FIGURE 57 MIDDLE EAST & AFRICA TRANSFECTION MARKET: BY COUNTRY (2020)
FIGURE 58 MIDDLE EAST & AFRICA TRANSFECTION MARKET: BY COUNTRY (2021 & 2028)
FIGURE 59 MIDDLE EAST & AFRICA TRANSFECTION MARKET: BY COUNTRY (2020 & 2028)
FIGURE 60 MIDDLE EAST & AFRICA TRANSFECTION MARKET: BY TYPE (2021-2028)
FIGURE 1 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
